Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07123038 · ClinicalTrials.gov registry record
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
A clinical trial of Rheumatoid Arthritis (RA) and Hidradenitis Suppurativa (HS), sponsored by Sonoma Biotherapeutics.
- Recruiting
- Registry status
- 36
- Enrollment target
- 10
- Study locations
NCT07123038: Recruiting study of Rheumatoid Arthritis (RA) and Hidradenitis Suppurativa (HS), sponsored by Sonoma Biotherapeutics.
NCT07123038 is a study of Rheumatoid Arthritis (RA) and Hidradenitis Suppurativa (HS) that is actively recruiting participants, run by Sonoma Biotherapeutics. The registered enrollment target is 36 participants, below the 266-participant average among 17 other Rheumatoid Arthritis (RA) trials with a reported enrollment target (86% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07123038, a study of Rheumatoid Arthritis (RA) and Hidradenitis Suppurativa (HS), is actively recruiting participants, sponsored by Sonoma Biotherapeutics.
- RECRUITING
- Registry status
- 36 participants
- Enrollment target
- 10
- Study locations
Study Summary
To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.
Conditions Studied
Interventions
- OTHER Long Term Safety Monitoring Procedures
Study Locations (10)
Massachusetts
- Tufts University - Boston
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
California
- UCSF Medical Center - San Francisco
- Stanford Medical Center - Stanford
Colorado
- University of Colorado - Aurora
Illinois
- Northwestern University - Chicago
Minnesota
- University of Minnesota - Minneapolis
North Carolina
- Duke University - Durham
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-07-22 |
| Est. Completion | 2040-12 |
What NCT07123038 shows while recruiting
NCT07123038 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 266-participant average among 17 other Rheumatoid Arthritis (RA) trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Rheumatoid Arthritis (RA) appearing as the primary indexed condition, and to 1 intervention - of which Long Term Safety Monitoring Procedures is the first listed.
NCT07123038 lists 10 locations in 7 states (Massachusetts, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT07123038 about?
NCT07123038 is a clinical study titled "A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic". To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.
What is the current status of trial NCT07123038?
This trial is currently recruiting. The enrollment target is 36 participants. The study started on 2025-07-22. Estimated completion is 2040-12.
What conditions does trial NCT07123038 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT07123038?
The interventions under investigation include: Long Term Safety Monitoring Procedures (OTHER).
Who is sponsoring clinical trial NCT07123038?
This trial is sponsored by Sonoma Biotherapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07123038 being conducted?
This trial has 10 study locations across California, Colorado, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis (RA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07123038's enrollment target sits among peer trials
36 18th of 17 the lowest of 17 other Rheumatoid Arthritis (RA) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis (RA) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]
RECRUITING · NA
-
Probiotics in Adults With Rheumatoid Arthritis
RECRUITING · NA
-
Dose Response of Exercise for Arthritis Management
RECRUITING · NA
-
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI